PACB

#3014
Pacific Biosciences of California, Inc. - Common Stock
1.4 0 USD
-0.10%
Market Price
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
1.40
1.40
Yıllık Aralık
1.07
2.73
Günlük Değişim
-9.68%
Aylık Değişim
-4.76%
6 Aylık Değişim
-12.50%
Yıllık Değişim
+7.69%
Önceki Kapanış
1.5 5
Open
1.4 0
Düşük
1.4 0
Yüksek
1.4 0
Hacim
53
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Documents

2026

Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, 03 August 2020

Full document

Pacific Biosciences of California, Inc. (PACB) - Form 8-K Summary

Business Context and Reporting Period

This Current Report (Form 8-K) was filed on August 3, 2020, by Pacific Biosciences of California, Inc. The filing primarily serves to announce the Company's financial results for the second fiscal quarter ended June 30, 2020, and to disclose a significant change in executive leadership.

Key Financial Metrics

The filing text references a press release (Exhibit 99.1) containing the detailed financial results for the second quarter of 2020. However, the specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not included in the body of this Form 8-K document. The filing text does not provide a clear value for these metrics.

Material Changes and Executive Leadership

A material change in the Company's executive team was announced under Item 5.02:

  • Appointment: Ben Gong was appointed as Interim Chief Financial Officer and designated as the principal financial officer, effective August 8, 2020.
  • Departure: Susan K. Barnes will retire as Executive Vice President, Chief Financial Officer, and principal financial officer on August 7, 2020.
  • Background: Mr. Gong has been with the Company since May 2010, previously serving as Vice President of Finance and Treasurer.

Guidance, Outlook, and Risks

The filing text does not contain specific guidance, outlook, management commentary, or risk factors. These details are contained within the referenced press release (Exhibit 99.1) which is furnished but not filed as part of this specific text.

Investor Verification Checklist

  • Review the attached press release (Exhibit 99.1) for specific Q2 2020 revenue, net loss, and cash position figures.
  • Verify the transition timeline for the Chief Financial Officer role between August 7 and August 8, 2020.
  • Confirm if the press release includes updated full-year 2020 financial guidance.
  • Check for any subsequent filings regarding the permanent appointment of a Chief Financial Officer following Mr. Gong's interim tenure.

Haberler